NCT05843188View on ClinicalTrials.gov

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

April 24, 2026

Study Completion Date

October 24, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Hydroxychloroquine

Anti-Inflammatory - antimalarial - aminoquinolines

DRUG

Irinotecan

Antineoplastic agent

DRUG

Leucovorin

Folic acid derivative

DRUG

Fluorouracil

Antineoplastic agent

DRUG

Bevacizumab

Antineoplastic agent

Trial Locations (2)

M4N 3M5

Sunnybrook Odette Cancer Centre, Toronto

M5G2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT05843188 - Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter